Mini-series: I. Basic science. Uncertainty and inaccuracy of predicting CYP-mediated in vivo drug interactions in the ICU from in vitro models: Focus on CYP3A4

Intensive Care Medicine

Volumn 35, Issue 3, 2009, Pages 417-429

  Mouly, Stéphane ^a,b   Meune, Christophe ^a   Bergmann, Jean François ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Caco 2 cells; Cytochrome P450 3A4; Drug drug interactions; Human liver microsomes; P glycoprotein

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIASTHMATIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CISAPRIDE; CORTICOSTEROID; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; MIBEFRADIL; MUSCLE RELAXANT AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; PROTON PUMP INHIBITOR; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG;

COMPUTER ANALYSIS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG SCREENING; DRUG USE; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTENSIVE CARE UNIT; LIVER MICROSOME; MEDICAL RESEARCH; REVIEW; UNSPECIFIED SIDE EFFECT;

CACO-2 CELLS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENTEROCYTES; ENZYME INHIBITORS; HUMANS; INTENSIVE CARE UNITS; MICROSOMES, LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SPECIES SPECIFICITY;

EID: 60449088075     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-008-1384-1     Document Type: Review

References (77)

1. DR Romac TE Albertson 1999 Drug interactions in the intensive care unit Clin Chest Med 20 385 399
2. GK Dresser DG Bailey 2002 A basic conceptual and practical overview of interactions with highly prescribed drugs Can J Clin Pharmacol 9 191 198
3. BA Dubaybo JD Dingell 2005 Adverse drug reactions in the ICU Chest 128 1100 1101
4. HJ Mann 2006 Drug-associated disease: cytochrome P450 interactions Crit Care Clin 22 329 345
5. DS Streetman 2000 Metabolic basis of drug interactions in the intensive care unit Crit Care Nurse Q 22 1 13
6. C Stocker DJ Penny CP Brizard AD Cochrane R Soto LS Shekerdemian 2003 Intravenous sildenafil and inhaled nitric oxide: a randomized trial in infants after cardiac surgery Intensive Care Med 29 1996 2003
7. JA Myburgh RN Upton C Grant A Martinez 2001 Epinephrine, norepinephrine and dopamine infusions decrease propofol concentrations during continuous propofol infusion in an ovine model Intensive Care Med 27 276 282
8. R Pimenta Riechelmann F Moreira O Smaletz ED Saad 2005 Potential for drug interactions in hospitalized cancer patients Cancer Chemother Pharmacol 56 286 290
9. P Carbonin M Pahor R Bernabei A Sgadari 1991 Is age an independent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 39 1093 1099
10. M Shou 2005 Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data Curr Opin Drug Discov Devel 8 66 77
11. RJ Weaver 2001 Assessment of drug-drug interactions: concept and approaches Xenobiotica 31 499 508
12. JH Lin AY Lu 1998 Inhibition and induction of cytochrome P450 and the clinical implications Clin Pharmacokinet 35 361 390
13. S Fruhwald E Herk T Petnehazy S Scheidl P Holzer F Hammer H Metzler 2002 Sulfentanil potentiates the inhibitory effect of epinephrine on intestinal motility Intensive Care Med 28 74 80
14. N Van Brandt P Hantson Y Horsmans P Mahieu RK Verbeeck 1998 Effect of enteral versus parenteral feeding on hepatic blood flow and steady-state propofol pharmacokinetics in ICU patients Intensive Care Med 24 795 800
15. L Huang A Quartin D Jones DV Havlir 2006 Intensive care of patients with HIV infection N Engl J Med 355 173 181
16. O Pelkonen M Turpeinen J Uusitalo A Rautio H Raunio 2005 Prediction of drug metabolism and interactions on the basis of in vitro investigations Basic Clin Pharmacol Toxicol 96 167 175
17. PG Cuddy 2000 Monitoring drug therapy in the intensive care unit Crit Care Nurs Q 22 14 22
18. RM Goldberg J Mabee L Chan S Wong 1996 Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population Am J Emerg Med 14 447 450
19. S Zhou SY Chan BC Goh E Chan W Duan M Huang HL McLeod 2005 Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clin Pharmacokinet 44 279 304
20. L Pichard I Fabre G Fabre J Domergue B Saint-Aubert G Mourad P Maurel 1990 Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes Drug Metab Dispos 18 595 606
21. UA Meyer 1996 Overview of enzymes of drug metabolism J Pharmacokinet Biopharm 24 449 459
22. VJ Wacher JA Silverman Y Zhang LZ Benet 1998 Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics J Pharm Sci 87 1322 1329
23. LZ Benet T Izumi Y Zhang JA Silverman V Wacher 1999 Intestinal transport proteins and P-450 enzymes as barriers to oral drug delivery J Controlled Release 62 25 31
24. JR Kunta PJ Sinko 2004 Intestinal drug transporters: in vivo function and clinical importance Curr Drug Metab 5 109 124
25. WC Lau PA Gurbel PB Watkins CJ Neer AS Hopp DGM Carville KE Guyer AR Tait ER Bates 2004 Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 166 171
26. Y Gashe Y Daali M Fathi A Chiappe S Cottini P Dayer J Desmeules 2004 Codeine intoxication associated with ultrarapid CYP2D6 metabolism N Engl J Med 351 2827 2831
27. MW Lo MR Goldberg JB McCrea H Lu CI Furtek TD Bjornsson 1995 Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Clin Pharmacol Ther 58 641 649
28. SA Wrighton JC Stevens 1992 The human hepatic cytochromes P450 involved in drug metabolism Crit Rev Toxicol 22 1 15
29. LS Kaminsky MJ Fasco 1992 Small intestinal cytochromes P450 Crit Rev Toxicol 21 407 422
30. DW Nebert DW Russell 2002 Clinical importance of the cytochromes P450 Lancet 360 1155 1162
31. EV Hersh PA Moore 2004 Drug interactions in dentistry. The importance of knowing your CYPs JADA 135 298 311
32. BS Mayhew DR Jones SD Hall 2000 An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation Drug Metab Dispos 28 1031 1037
33. Y Lin P Lu C Tang Q Mei G Sandig AD Rodrigues TH Rushmore M Shou 2001 Substrate inhibition kinetics for cytochrome P450-catalyzed reactions Drug Metab Dispos 29 368 374
34. ML Schrag LC Wienkers 2001 Triazolam substrate inhibition: Evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site Drug Metab Dispos 29 70 75
35. RJ Bertz GR Granneman 1997 Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions Clin Pharmacokinet 32 210 258
36. S Mouly N Rizzo-Padoin G Simoneau C Verstuyft G Aymard C Salvat I Mahe JF Bergmann 2006 Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients Br J Clin Pharmacol 62 200 209
37. E Tanaka Y Takano S Inomata H Toyooka K Honda 2004 Premedication medicines do not cause drug metabolic interaction with propofol using human liver microsomes in vitro Eur J Clin Pharmacol 60 565 568
38. MH Court SX Duan LM Hesse K Venkatakrishnan DJ Greenblatt 2001 Cytochrome P-450 2B6 is responsible for interindividual variability of propofol hydroxylation by human liver microsomes Anesthesiology 94 110 119
39. JM Pascussi L Drocourt JM Fabre P Maurel MJ Vilarem 2000 Dexamethasone induces pregnane X receptor and retinoid X receptor-α expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators Mol Pharmacol 58 361 372
40. E Hustert A Zibat E Presecan-Siedel R Eiselt R Mueller C Fuss I Brehm U Brinkmann M Eichelbaum L Wojnowski O Burk 2001 Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4 Drug Metab Dispos 29 1454 1459
41. LC Quattrochi PS Guzelian 2001 CYP3A regulation: from pharmacology to nuclear receptors Drug Metab Dispos 29 615 622
42. MF Paine M Khalighi JM Fisher DD Shen KL Kunze CL Marsh JD Perkins KE Thummel 1997 Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism J Pharmacol Exp Ther 283 1552 1562
43. FP Guengerich 1999 Cytochrome P-450 3A4: regulation and role in drug metabolism Annu Rev Pharmacol Toxicol 39 1 17
44. 14C N-methyl] erythromycin breath test in healthy male volunteers J Clin Pharmacol 38 492 495
45. JS McCune RL Hawke EL LeCluyse HH Gillenwater G Hamilton J Ritchie C Lindley 2000 In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone Clin Pharmacol Ther 68 356 366
46. W Huang YS Lin DJ McConn II JC Calamia RA Totah N Isoherranen M Glodowski KE Thummel 2004 Evidence of significant contribution from CYP3A5 to hepatic drug metabolism Drug Metab Dispos 32 1434 1445
47. KE Thummel 2004 A genetic test for immunosuppressant dose selection? Pharmacogenetics 14 145 146
48. AP Koley JT Buters RC Robinson A Markowitz FK Friedman 1995 CO-binding kinectics of human cytochrome P450 3A4 J Biol Chem 270 5014 5018
49. KE Kenworthy SE Clarke J Andrews JB Houston 2001 Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism Drug Metab Dispos 29 1644 1651
50. MF Paine MB Fisher 2000 Immunochemical identification of UGT isoforms in human small bowel and in Caco-2 cell monolayers Biochem Biophys Res Commun 273 1053 1057
51. RR Shah 2005 Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules Expert Opin Drug Saf 4 103 128
52. AT Fojo K Ueda DJ Slamon DG Poplack MM Gottesman I Pastan 1987 Expression of a multidrug-resistance gene in human tumors and tissues Proc Natl Acad Sci 84 265 269
53. SF Su JD Huang 1996 Inhibition of the intestinal digoxin absorption and exsorption by quinidine Drug Metab Dispos 24 142 147
54. MF Fromm RB Kim CM Stein GR Wilkinson DM Roden 1999 Inhibition of P-glycoprotein-mediated drug transport. A unifying mechanism to explain the interaction between digoxin and quinidine Circulation 99 552 557
55. K Ito T Iwatsubo S Kanamitsu Y Nakajima Y Sugiyama 1998 Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport Annu Rev Pharmacol Toxicol 38 461 499
56. Q Mei C Tang C Assang Y Lin D Slaughter A David Rodrigues TA Baillie TH Rushmore M Shou 1999 Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism J Pharmacol Exp Ther 291 749 759
57. GT Tucker JB Houston SM Huang 2001 EUFEPS conference report. Optimizing durg development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. European Federation of Pharmaceutical Sciences Eur J Pharm Sci 13 417 428
58. DM Stresser AP Blanchard SD Turner JCL Erve AA Dandeneau VP Miller CL Crespi 2000 Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates Drug Metab Dispos 28 1440 1448
59. RW Wang DJ Newton N Liu WM Atkins AYH Lu 2000 Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrates-dependent Drug Metab Dispos 28 360 366
60. J Andrews MF Abd-Ellah NL Randolph KE Kenworthy DJ Carlile T Friedberg JB Houston 2002 Comparative study of the metabolism of drug substrates by human cytochome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells Xenobiotica 32 937 947
61. SR Faucette H Wang GA Hamilton SL Jolley D Gilbert C Lindley B Yan N Masahiko EL Lecluyse 2004 Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers Drug Metab Dispos 32 348 358
62. SR Faucette TC Zhang R Moore T Suevoshi CJ Omiecinski EL Lecluyse M Negishi H Wang 2007 Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers J Pharmacol Exp Ther 320 72 80
63. J Staudinger Y Liu A Madan S Habeedu CD Klaassen 2001 Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor Drug Metab Dispos 29 1467 1472
64. D Smirlis R Muangmoonchai M Edwards IR Phillips EA Shephard 2001 Orphan receptor promiscuity in the induction of cytochromes P450 by xenobiotics J Biol Chem 276 12822 12826
65. CA Woosley CM Coopersmith 2006 Vasoactive drugs and the gut: is there anything new? Curr Opin Crit Care 12 155 159
66. SD Hall KE Thummel PB Watkins KS Lown LZ Benet MF Paine RR Mayo K Turgeon DG Bailey RJ Fontana SA Wrighton 1999 Molecular and physical mechanisms of first-pass extraction Drug Metab Dispos 27 161 166
67. MF Paine HL Hart SS Ludington RL Haining AE Rettie DC Zeldin 2006 The human intestinal cytochrome P450 "pie" Drug Metab Dispos 34 880 886
68. S Mouly MF Paine 2003 P-glycoprotein increases from proximal to distal regions of human small intestine Pharm Res 20 1595 1599
69. VJ Wacher CY Wu LZ Benet 1995 Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy Mol Carcinog 13 129 134
70. Pinto M, Robine-Leon S, Appay M-D, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simon-Assmann, Haffen C, Fogh J, Zweibaum A (1983) Enterocyte-like differenciation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323-330
71. P Schmiedlin-Ren KS Thummel JM Fisher MF Paine KS Lown PB Watkins 1997 Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1α, 25-dihydroxyvitamin D3 Mol Pharmacol 51 741 754
72. S Mouly MF Paine PB Watkins 2004 Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir J Pharmacol Exp Ther 308 941 948
73. JM Fischer SA Wrighton JC Calamia DD Shen KL Kunze KE Thummel 1999 Midazolam metabolism by modified Caco-2 monolayers: effects of extracellular protein binding J Pharmacol Exp Ther 289 1143 1150
74. L Barthe J Woodley G Houin 1999 Gastrointestinal absorption of drugs: methods and studies Fundam Clin Pharmacol 13 154 168
75. P Baranczewski A Stanczak K Sundberg R Svensson A Wallin J Jansson P Garberg H Postlind 2006 Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development Pharmacol Rep 58 453 472
76. P Bonnabry J Sievering T Leemann P Dayer 1999 Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system fro drug metabolism interactions Eur J Clin Pharmacol 55 341 347
77. A Rostami-Hodjegan GT Tucker 2007 Simulation and prediction of in vivo drug metabolism in human population from in vitro data Nat Rev Drug Discov 6 140 148